Verastem, Inc. (VSTM:NASDAQ) closed at $10.00 on October 26, 2026, down 0.40% on the day. The stock trades 7.6% below its 52-week high of $10.82 and 191.5% above its 52-week low of $3.43. Over the past year, it gained 14.7%. Verastem, Inc. is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since October 24, 2025, VSTM closed higher on 124 days (49%). Its best day was November 17, 2025 (+21.03%) and its worst was November 4, 2025 (-20.10%). The stock moved 10% or more in a single session 7 times. It opened at least 5% above the previous day's high 1 time.
Verastem, Inc., a biopharmaceutical company, focuses on discovering and developing drugs targeting cancer stem cells (CSCs). Its programs target the focal adhesion kinase (FAK) and the PI3K/mTOR signaling pathways. The company's product candidate FAK inhibitor, VS-6063, is in Phase 1 study in combination with PD-1 inhibitor pembrolizumab and gemcitabine for pancreatic cancer; a Phase Ib clinical trial in combination with paclitaxel for patients with ovarian cancer; a Phase II study in patients with non-small cell lung cancer; a Phase II trial preceding surgery in mesothelioma; and a Phase 1/1b clinical trail in combination with avelumab in patients with ovarian cancer, as well as a combination trial of VS-6063 and VS-5584 in patients with relapsed mesothelioma. It is also developing FAK inhibitor, VS-4718 that is in Phase 1, single-agent, dose escalation trial in patients with advanced cancers; and a Phase 1, dose-escalation clinical trial in combination with gemcitabine and nab-paclitaxel in patients with advanced solid tumors, as well as a Phase 1, dose-escalation clinical trial of PI3K/mTORC1/2 inhibitor, VS-5584, in patients with advanced non-hematologic malignancies or lymphom...
Find more stocks like VSTM with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.